Trans Genic Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Trans Genic Inc with three other
companies in this sector in Japan:
Medical Data Vision Co Ltd
sales of 3.58 billion Japanese Yen [US$32.34 million]
Japan Tissue Engineering Company Limited
(2.27 billion Japanese Yen [US$20.53 million]
of which 61%
was Regenerative Medicine Products Business), and
Symbio Pharmaceuticals Ltd
(3.84 billion Japanese Yen [US$34.67 million]
During the year ended March of 2018, sales at
Trans Genic Inc were ¥3.60 billion (US$32.56 million).
increase of 56.4%
versus 2017, when the company's sales were ¥2.30 billion.
This was the fifth consecutive year of sales increases at Trans Genic Inc
(and since 2013, sales have increased a total of 411%).
Sales of Eliminations and Corporate saw an increase
112.1% in 2018, from
¥1.65 million to ¥3.50 million.
Not all segments of Trans Genic Inc experienced an increase in sales in 2018:
sales of Genomics Business fell 29.8% to ¥294.88 million.
Trans Genic Inc also experienced decreases in sales in
Cro Business (down 13.0% to ¥992.33 million)
Pathological Diagnosis Business (down 0.9% to ¥395.63 million)